Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

Published Date: 01 Sep 2023

A recent study found an association between the treatment for chronic myeloid leukemia (CML) with nilotinib (a tyrosine kinase inhibitor).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

2.

PFS in R/R Mantle Cell Lymphoma is Improved by Ibrutinib-Venetoclax.

3.

Nasal therapeutic HPV vaccine could prevent cervical cancer

4.

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

5.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot